Display options
Cite
Liu Y, Dalal K. Review of cost-effectiveness analysis of medical treatment for myocardial infarction. Int J Prev Med. 2011;2(2):64-72
Liu, Y., & Dalal, K. (2011). Review of cost-effectiveness analysis of medical treatment for myocardial infarction. International journal of preventive medicine, 2(2), 64-72.
Liu, Yanmei, and Dalal, Koustuv. "Review of cost-effectiveness analysis of medical treatment for myocardial infarction." International journal of preventive medicine vol. 2,2 (2011): 64-72.
Liu Y, Dalal K. Review of cost-effectiveness analysis of medical treatment for myocardial infarction. Int J Prev Med. 2011 Apr;2(2):64-72. PMID: 21603010; PMCID: PMC3093774.
Copy Download .nbib Format: NLM
Share it on

Int J Prev Med. 2011 Apr;2(2):64-72.

Review of cost-effectiveness analysis of medical treatment for myocardial infarction.

International journal of preventive medicine

Yanmei Liu, Koustuv Dalal

Affiliations

  1. MPH Student, Karolinska Institutet, Sweden.

PMID: 21603010 PMCID: PMC3093774

Abstract

OBJECTIVES: Myocardial infarction (MI) is a leading cause of death in both the industrialized and developing countries globally. The economic evaluation of MI is undertaken to rationale the allocation of scarce healthcare resource. The objective is to review cost-effectiveness analysis of MI with medications.

METHODS: WE SEARCHED PUBMED USING THE KEY WORDS: "cost effectiveness analysis"and "myocardial infarction" After applying the selection criteria, eight articles were selected for the present study.

RESULTS: Out of eight articles, five had studied thrombolytic agents. All of these papers clearly explain the costs and benefits of different drugs for MI. ICER was assessed in six out of the eight articles to compare the costs and health effects between alternative medications. ICER was expressed in different effect units.

CONCLUSIONS: This study found that various medications including thrombolytic agents, ACEI and heparin are administered to treat MI in many countries. It is also found that five of eight studies focus on thrombolytic therapies. It implies that thrombolytic is generally very cost effective for MI to the whole society.

Keywords: Cost effectiveness Analysis; Heart; Medicine

References

  1. BMJ. 1992 Sep 5;305(6853):548-53 - PubMed
  2. Heart. 2008 Jun;94(6):679-84 - PubMed
  3. Expert Opin Pharmacother. 2008 Jan;9(1):95-105 - PubMed
  4. N Engl J Med. 2006 Apr 6;354(14):1477-88 - PubMed
  5. Eur Heart J. 2007 Jul;28(13):1598-660 - PubMed
  6. J Am Coll Cardiol. 2001 Jun 15;37(8):2215-39 - PubMed
  7. N Engl J Med. 1993 Sep 2;329(10):673-82 - PubMed
  8. Arch Mal Coeur Vaiss. 1989 Oct;82 Spec No 3:55-62 - PubMed
  9. Lancet. 1992 Mar 28;339(8796):753-70 - PubMed
  10. Can J Cardiol. 2009 Dec;25(12):e399-405 - PubMed
  11. J Am Coll Cardiol. 2009 Sep 29;54(14):1271-9 - PubMed
  12. Lancet. 1994 May 7;343(8906):1115-22 - PubMed
  13. JAMA. 1992 Mar 25;267(12):1669-75 - PubMed
  14. Eur Heart J. 1998 Oct;19(10):1518-24 - PubMed
  15. N Engl J Med. 1986 Jun 5;314(23):1465-71 - PubMed
  16. Am Heart J. 2005 Apr;149(4):637-44 - PubMed
  17. Am Heart J. 2005 Feb;149(2):217-26 - PubMed
  18. Eur Heart J. 1993 Jan;14(1):75-83 - PubMed
  19. Br Heart J. 1988 May;59(5):527-34 - PubMed
  20. J Am Coll Cardiol. 1999 Sep;34(3):890-911 - PubMed
  21. Eur Heart J. 1992 Jan;13(1):2-8 - PubMed
  22. Lancet. 1988 Mar 12;1(8585):545-9 - PubMed
  23. Pharmacoeconomics. 1998 Mar;13(3):337-46 - PubMed
  24. Ann Intern Med. 1990 Jul 15;113(2):147-54 - PubMed
  25. Clin Cardiol. 1997 Nov;20(11 Suppl 3):III6-10 - PubMed

Publication Types